Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran

• Published in: PloS one 2015-05, Vol.10 (5), p.e0126955-e0126955
• Main Authors: Memarnejadian, Arash, Menbari, Shahoo, Mansouri, Seyed Ali, Sadeghi, Leila, Vahabpour, Rouhollah, Aghasadeghi, Mohammad Reza, Mostafavi, Ehsan, Abdi, Mohammad
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adult; AIDS; Anti-HIV Agents - pharmacology; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Antiviral agents; Chronic infection; Cross-Sectional Studies; Deduction; Disease transmission; Drug abuse; Drug resistance; Drug Resistance, Viral; Drug Users; Drugs; Female; Gene sequencing; Genes, Viral; Genomes; Genotype; HIV; HIV Infections - epidemiology; HIV Infections - transmission; HIV Infections - virology; HIV Seropositivity; HIV-1 - drug effects; HIV-1 - genetics; Human immunodeficiency virus; Humans; Inhibitors; Injection; Iran - epidemiology; Male; Medical screening; Microbial Sensitivity Tests; Mutation; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleosides; Phylogeny; Protease; Protease inhibitors; Proteinase inhibitors; Risk Factors; RNA-directed DNA polymerase; Seroconversion; Surveillance; Therapy
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0126955

The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist about the rate of these primary resistance mutations among the ART-naïve, chronically infected individuals who are, in fact, the main candidates for ART initiation. To address this issue, we collected blood samples from 40 ART-naïve injection drug-users (IDUs) with chronic HIV-1 infection (seroconversion time ranging from 2 to 9 years) living in Sanandaj, Iran, followed by sequencing of the protease and reverse-transcriptase regions from their HIV-1 genome. Phylogenetic analyses of the sequenced regions revealed that all samples were CRF35_AD. Transmitted resistance mutations were interpreted as surveillance drug-resistant mutations (SDRMs) based on the world health organization (WHO) algorithm. The frequency of SDRMs to any class of antiretroviral drugs was 15%, which included mutations to nucleoside reverse transcriptase inhibitors (NRTIs, 10%), with M41L and M184V as the most common (5%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs, 5%), with K103N as the only detected mutation (5%). Although not in the WHO SDRMs list, several minor protease inhibitor resistant mutations listed in the International Antiviral Society-USA panel were identified, of which M36I, H69K, L89M/V/I (each one 100%) and K20R/T (92.5%) can be considered as polymorphic signatures for CRF35_AD.The relatively high rate of TDR mutations in our study raises concerns about the risk of treatment failure in chronically infected IDUs of Sanandaj city. These results suggest that routine resistance testing should be considered before the therapy initiation in this area. Additional surveillance studies are required to generalize this deduction to other cities of Iran.